Q4 2024 · 13F-HR
Opaleye Management Inc.holdings as filed
Filed 2025-02-14 · accession 0001493152-25-006852
$571.4M
Reported value
39
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 415858109 | HROW | HARROW HEALTH INC | $133.9M | 23.4% | 3,990,000 | Common | SOLE |
| 88322Q108 | TGTX | TG THERAPEUTICS INC | $68.0M | 11.9% | 2,260,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $42.2M | 7.38% | 8,840,000 | Common | SOLE |
| 29772L108 | ETON | ETON PHARMACEUTICALS INC | $38.0M | 6.65% | 2,852,070 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $37.1M | 6.49% | 4,342,500 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $33.6M | 5.89% | 1,625,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $28.0M | 4.90% | 500,000 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $21.7M | 3.79% | 2,040,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $20.0M | 3.49% | 1,698,142 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $12.8M | 2.24% | 480,000 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS | $11.8M | 2.06% | 1,200,000 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $10.8M | 1.89% | 750,000 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $9.6M | 1.69% | 1,825,000 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $9.5M | 1.67% | 2,317,500 | Common | SOLE |
| 471871202 | JSPR | JASPER THERAPEUTICS INC | $8.6M | 1.50% | 400,000 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $8.4M | 1.46% | 325,000 | Common | SOLE |
| 00445A100 | — | ACELYRIN INC | $7.2M | 1.26% | 2,235,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $7.1M | 1.25% | 378,500 | Common | SOLE |
| 98419J206 | XOMA | XOMA CORP DEL | $6.6M | 1.15% | 250,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $6.1M | 1.07% | 75,000 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $6.1M | 1.07% | 11,500,000 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $5.4M | 0.94% | 1,767,500 | Common | SOLE |
| 09075X108 | — | BIODESIX INC | $5.3M | 0.93% | 3,465,000 | Common | SOLE |
| 48576UAA4 | — | KARYOPHARM THERAPEUTICS INC | $4.7M | 0.82% | 6,000,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $4.6M | 0.80% | 58,500 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $4.1M | 0.71% | 4,490,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $4.1M | 0.71% | 105,000 | Common | SOLE |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $4.0M | 0.69% | 2,209,998 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $2.8M | 0.49% | 965,000 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $2.3M | 0.41% | 220,000 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $2.3M | 0.40% | 465,000 | Common | SOLE |
| N44445109 | IMTX | IMMATICS NV | $1.2M | 0.21% | 165,000 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $918,750 | 0.16% | 375,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $855,400 | 0.15% | 130,000 | Common | SOLE |
| 75901B107 | RGNX | REGENXBIO Inc | $618,400 | 0.11% | 80,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES | $613,200 | 0.11% | 280,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $416,900 | 0.07% | 110,000 | Common | SOLE |
| 86150R107 | STOK | STOKE THERAPEUTICS INC | $275,750 | 0.05% | 25,000 | Common | SOLE |
| 00534B100 | ADGM | ADAGIO MED HLDGS INC | $116,100 | 0.02% | 110,571 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.